Skip to main content

Generics

  • Mylan gets FDA nod for generic Adalat CC

    PITTSBURGH — The Food and Drug Administration has approved a generic drug for hypertension made by Mylan.

    Mylan announced Friday the approval of nifedipine extended-release tablets in the 30-mg, 60-mg and 90-mg strengths. The drug is a generic version of Bayer’s Adalat CC.

    Nifedipine tablets had sales of around $82 million during the 12-month period ended in June, according to IMS Health.

  • Amneal names SVP, general counsel

    BRIDGEWATER, N.J. — Amneal Pharmaceuticals has named a drug industry attorney as SVP and general counsel, the generic drug maker said Thursday.

    Amneal announced the appointment of Robert Loewenstein, who previously served as head of law firm Budd Larner, P.C.’s corporate generic pharmaceuticals practice.

  • Decision Resources: J&J, Merck chemotherapy drugs will emerge as go-to second-line treatments

    BURLINGTON, Mass. — Chemotherapy drugs made by Johnson & Johnson and Merck will become the standard second-line treatment for ovarian cancer within the decade, replacing a treatment made by Bristol-Myers Squibb and generic versions, according to a new report by market research firm Decision Resources.

  • Site helps open networking for pharm students, schools

    NEW YORK — The power of a professionally driven social networking and information platform is now within reach of pharmacists and pharmacy students. And students are taking a lead role in its development and growth.


    The new network is called Pharmacist Society. It was conceived and developed as a Web-based networking, information and practice tool by pharmacist Ted Search, president of Skipta — a provider of networking technology for health professionals — and by pharmacy students and educators.


  • Momenta, Sandoz file patent suit against Teva over generic Lovenox

    @font-face { font-family: "Times New Roman"; }p.MsoNormal, li.MsoNormal, div.MsoNormal { margin: 0in 0in 0.0001pt; font-size: 12pt; font-family: "Times New Roman"; }table.MsoNormalTable { font-size: 10pt; font-family: "Times New Roman"; }div.Section1 { page: Section1; }CAMBRIDGE, Mass. — Drug makers Momenta Pharmaceuticals and Sandoz have filed a lawsuit against Teva Pharmaceutical Industries in the U.S. District Court for the District of Massachusetts, alleging infringement of two patents related to a generic blood-thinning drug.

  • Reporters Notebook, Chain Pharmacy 12/13/10

    Supplier News — Fera Pharmaceuticals has recently launched two new topical ointments. The New York-based company has developed Ilotycin (erythromycin) and Garamycin (gentamicin) ophthalmic ointments, both for the treatment of bacterial infections of the eye. “Our goal is simple: to keep more quality healthcare choices alive for the people who need them,” company co-founder Frank DellaFera said.


    


  • Watson, Natco ink deal for generic Revlimid

    MORRISTOWN, N.J. — U.S. generic drug maker Watson Pharmaceuticals and Indian drug maker Natco Pharma will work together to develop and commercialize a generic drug used for bone marrow disorders, the two companies said Tuesday.

    The agreement concerns lenalidomide tablets in the 5-mg, 10-mg, 15-mg and 25-mg strengths. The drug is a generic version of Celgene’s Revlimid, used to treat the plasma cell cancer multiple myeloma and myelodysplastic syndrome. Myelodysplastic syndrome results from the bone marrow producing blood cells that are misshapen.

  • NACDS urges simple, single med document for patients

    ALEXANDRIA, Va. — Simplify, simplify.


X
This ad will auto-close in 10 seconds